HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2007.086215v1 53/7/1306    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Reinshagen, M. Articles by von Ahsen, N. Search for Related Content PubMed PubMed Citation Articles by Reinshagen, M. Articles by von Ahsen, N. Related Collections Drug Monitoring and Toxicology

6-Thioguanine Nucleotide–Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial

¹ Department of Medicine I, Klinikum Braunschweig, Germany.
² Department of Clinical Chemistry, University of Göttingen, Germany.
³ Clinical Research and Development, Merckle GmbH Ulm, Germany.
⁴ Department of Medicine I, University of Ulm, Germany.
⁵ Department of Internal Medicine II, Saarland University, Homburg, Germany.
⁶ Department of Medicine I, University of Regensburg, Germany.
⁷ Department of Medicine I - ZAFES, University of Frankfurt, Germany.
⁸ Evangelisches Krankenhaus Kalk, University of Cologne, Germany.

^aAddress correspondence to this author at: Medizinische Klinik I, Klinikum Braunschweig, Salzdahlumer Straße 90 8, 38126 Braunschweig, Germany. Fax 49-531-595-2653; e-mail m.reinshagen{at}klinikum-braunschweig.de.

Background: A prospective randomized trial in patients with Crohn disease studied whether 6-thioguanine nucleotide (6-TGN) concentration–adapted azathioprine (AZA) therapy is clinically superior to a standard dose of 2.5 mg/kg/day AZA.

Methods: After 2 weeks of standard therapy, patients (n = 71) were randomized into standard (n = 32) or adapted-dose (n = 25) groups; 14 patients dropped out before randomization. In the adapted group, the AZA dose was adjusted to maintain 6-TGN concentrations between 250 and 400 pmol/8 x 10⁸ erythrocytes (Ery). Response criteria were the number of patients in remission after 16 weeks without steroids (primary) and remission after 24 weeks, frequency of side effects, and quality of life (secondary).

Results: After 16 weeks, 14 of 32 (43.8%) patients in the standard group vs 11 of 25 (44%) in the adapted group were in remission without steroids (intent-to-treat analysis). After 24 weeks, 43.8% vs 40% were in remission. No significant differences were found concerning quality of life, disease activity, 6-TGN concentrations, AZA dose, or dropouts due to side effects. Sixty-six patients had a wild-type thiopurine S-methyltransferase (TPMT) genotype, with TPMT activities of 8 to 20 nmol/(mL Ery x h). Five patients (dropouts after randomization) were heterozygous, with TPMT activities <8 nmol/(mL Ery x h). 6-Methyl mercaptopurine (6-MMP) concentrations >5700 pmol/8 x 10⁸ Ery were not associated with hepatotoxicity.

Conclusion: Standard and adapted dosing with the provided dosing scheme led to identical 6-TGN concentrations and remission rates. Adapted dosing had no apparent clinical benefit for patients with TPMT activity between 8 and 20 nmol/(mL Ery x h). Additionally, 6-MMP monitoring had no predictive value for hepatotoxicity.

The following articles in journals at HighWire Press have cited this article:

				P. de Graaf, N. K.H. de Boer, B. Jharap, C. J.J. Mulder, A. A. van Bodegraven, and A. I. Veldkamp Stability of Thiopurine Metabolites: A Potential Analytical Bias Clin. Chem., January 1, 2008; 54(1): 216 - 218. [Full Text] [PDF]